A prominent Boston oncologist is downplaying comments he made at an invitation-only event last week that quickly spread among investors and set off alarm bells about an experimental multiple myeloma cell therapy from Bluebird Bio (BLUE) and Celgene (CELG).
Dr. Ken Anderson, a multiple myeloma expert at the Dana-Farber Cancer Institute, told investors attending the Cowen Health Care Conference on March 13 that three patients under his care suffered relapses after treatment with bb2121, the CAR-T therapy invented by Bluebird and licensed to Celgene.
About the Author Reprints
Hmmm.
No comment